Bionical Emas Secures Exclusive Partnership to Address Critical European Fluorouracil Shortage
核心洞察
Bionical Emas (搜索) has secured an exclusive global clinical trial supply agreement with German pharmaceutical company Pharma Resources GmbH (搜索) to distribute EU-marketed oncology injectables, including Fluorouracil.
The partnership addresses critical 5-Fluorouracil shortages that are currently disrupting cancer treatments and clinical trials across Europe.
Bionical Emas (搜索)' global infrastructure and agile supply model will reduce delivery times from months to weeks for essential oncology medications.
Bionical Emas (搜索), a global provider of Clinical Trial Services, has announced an exclusive global clinical trial supply agreement with Pharma Resources GmbH (搜索), a German pharmaceutical company specialized in oncology. The strategic partnership grants Bionical Emas exclusive rights to distribute Pharma Resources' EU-marketed oncology injectables, including Fluorouracil, which is currently experiencing critical shortages across Europe.
Addressing Critical Drug Shortages
The agreement comes at a crucial time when 5-Fluorouracil shortages are disrupting cancer treatments and clinical trials throughout Europe. As the sole distributor, Bionical Emas (搜索) will streamline access to Pharma Resources' oncology portfolio for pharmaceutical companies, contract research organizations (CROs), and clinical trial providers worldwide.
Bionical Emas (搜索)' global infrastructure and agile supply model is designed to cut delivery times from months to weeks, ensuring faster and more reliable access to essential medications. The partnership combines advanced demand forecasting with proactive inventory strategies to address long-standing supply chain challenges, accelerating trial timelines and improving flexibility for investigational sites.
Strategic Market Entry
This collaboration marks Pharma Resources' entry into the clinical trial supply market while strengthening Bionical Emas (搜索)' position as a trusted supply partner. The agreement highlights Bionical Emas' continued success in forging impactful global alliances within the pharmaceutical industry.
Tom White, Senior Vice-President of Strategic Alliances at Bionical Emas (搜索), commented: "This strategic agreement underscores our unwavering commitment to delivering innovative, patient-focused solutions to the clinical trial community. With our global infrastructure and established expertise in the industry, Pharma Resources has proven to be an exceptionally dedicated and agile partner, and together we're ensuring uninterrupted access to vital oncology treatments for patients worldwide."
Juliana Dodillet, Managing Director at Pharma Resources, stated: "We are thrilled to partner with Bionical Emas (搜索), whose proven global reach and deep expertise in clinical trial supply make them the ideal partner to support the launch of our first clinical trial supply program and maximize the reach of our oncology injectable portfolio. This collaboration ensures our products can support the development of new therapies and improve patient outcomes, particularly at a time when Fluorouracil shortages are significantly impacting access across Europe."
Company Profiles
Bionical Emas (搜索) operates as a global Clinical Trial Supply (CTS) and Early Access Programs (EAP) group, bringing life-changing medicines to patients around the world. The company's range of services and capabilities benefit many of the world's leading pharmaceutical and biotechnology companies.
Pharma Resources GmbH (搜索), based in Hameln, Germany, is a specialized company in the pharmaceutical industry focusing on generic oncology products. The company provides a full-service solution from regulatory approval to delivery, ensuring reliable and high-quality supply chains.